Details for Patent: 8,178,554

Summary for Patent: 8,178,554

Title:	Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
Abstract:	The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Inventor(s):	Maxime Lampilas, Jozsef Aszodi, David Alan Rowlands, Claude Fromentin
Assignee:	Allergan Pharmaceuticals International Ltd
Application Number:	US13/068,399
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 8,178,554: Scope, Claims, and Competitive Patent Landscape

US Patent 8,178,554 protects a specific small-molecule core and a narrow set of downstream uses and formulations centered on that core. The claim set is compact (6 claims) and stays tightly tethered to: (i) the compound identity, (ii) a single specific salt form (sodium), (iii) pharmaceutical compositions for oral or other standard dosage forms (not further limited in your claim text), and (iv) antibacterial treatment by administration.

What does US 8,178,554 actually claim?

1. Compound scope (independent claim)

Claim 1 is the only independent compound identity claim in the set you provided. It reads as a single, structurally defined molecule:

• Claim 1: Trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide or a pharmaceutically acceptable salt thereof.

Scope mechanics:

• The compound is defined by a rigid bicyclic scaffold and multiple substituents:
  • trans-configuration at 7-oxo context
  • sulphooxy substituent at position 6
  • carboxamide at position 2
  • 1,6-diazabicyclo[3,2,1]octane core
• “Pharmaceutically acceptable salt” expands coverage beyond free base to salts that meet acceptability criteria, but it does not explicitly enumerate salts other than the sodium salt in dependent claim 2.

2. Salt scope (dependent claim)

• Claim 2: The sodium salt of the compound according to claim 1.

Scope mechanics:

• This claim is narrower than claim 1 because it locks to the sodium salt form.
• It also provides a clear target for manufacturing and formulation competitors because salt form is often a critical quality attribute.

3. Composition scope (dependent claims)

• Claim 3: A pharmaceutical composition comprising the compound according to claim 1.
• Claim 4: A pharmaceutical composition comprising the compound according to claim 2.

Scope mechanics:

• These composition claims are broad in that they do not specify:
  • route (oral, IV, etc.)
  • dosage form (tablet, capsule, solution)
  • excipients
  • release profile
  • patient subgroup
• They are composition-by-ingredient claims. If a competitor makes a product that contains the claimed compound (free base and/or sodium salt depending on which claim is asserted), it can fall within the composition scope.

4. Method-of-treatment scope (dependent claims)

• Claim 5: A method of treating a bacterial infection comprising administering an effective amount of the compound according to claim 1.
• Claim 6: A method of treating a bacterial infection comprising administering an effective amount of the compound according to claim 2.

Scope mechanics:

• The method is defined by:
  • the therapeutic indication category: bacterial infection
  • the act: administering an effective amount of the claimed compound
• The claim text does not constrain:
  • bacterial species
  • site of infection (respiratory, urinary, etc.)
  • disease severity
  • combination with other agents
• This gives the claims a large functional “therapeutic coverage” band.

---

How broad is the patent’s practical protection?

Claim-by-claim breadth assessment

Claim	Category	Key limiter	What it covers in practice	What it does not cover (from text)
1	Compound	exact structure + trans configuration + “sulphooxy” + carboxamide	free base + any pharmaceutically acceptable salts that fit the compound identity	compounds that change the scaffold, substitution pattern, stereochemistry, or functional group identity
2	Salt	sodium salt only	manufacturing and formulations that use sodium salt form	other counterions (e.g., potassium, ammonium, calcium) unless they still qualify as “pharmaceutically acceptable salts” under claim 1
3	Composition	contains claim 1 compound	any formulation with the compound in any common dosage form, assuming no further limiting language	formulations that omit the compound or use a materially different active
4	Composition	contains claim 2 compound	sodium salt products	non-sodium salt formulations that rely only on claim 1
5	Method	“bacterial infection” + effective amount	broad antibacterial use assuming the treated condition is bacterial infection	exact organism/location not specified; combinations not specified
6	Method	sodium salt + bacterial infection	antibacterial use specifically with sodium salt active	other salt forms, unless asserted under claim 5

Practical interpretation

• The patent is not a “process” or “use in a specific disease subtype” patent. It is a direct product and therapeutic use patent centered on one molecule and one salt.
• The broadest threat to competitors is usually claim 1 (composition and method) because it can reach multiple salt forms; claim 2 is the sharper hook for sodium-salt-specific products.

---

What is the likely patent landscape structure around this compound?

A US compound-and-use patent of this type typically clusters in three layers:

1. Core-structure coverage (compound claims like claim 1)
2. Salt-form and formulation coverage (claim 2-4)
3. Therapeutic use coverage (claim 5-6), often tied to antibacterial indication language and sometimes broader class claims in sibling filings

Landscape implications from the claim set itself

Even without reading the specification, the claim drafting suggests the following competitive zones:

A. Competitors making the same molecule

• Direct infringement risk rises sharply if a competitor’s active ingredient matches the exact trans-7-oxo-sulphooxy bicyclic carboxamide scaffold (claim 1) or the sodium salt (claim 2).
• Formulation variants are not safe harbors under claim 3/4 because the composition claims are ingredient-based.

B. Competitors making other salts of the same molecule

• If a competitor uses a different counterion for the same free base compound, it can still land within claim 1 as a “pharmaceutically acceptable salt.”
• The only clear way to avoid claim 1 on salt grounds would be to use a non-acceptable salt (rare commercially) or a different compound structure.

C. Competitors changing the active structure slightly

• Any change that removes or alters the key structural identity (bicyclic scaffold, the sulphooxy group placement, the carboxamide position, or stereochemical configuration) likely escapes literal scope of claim 1.
• That pushes infringement risk into doctrine-of-equivalents territory, which depends on prosecution history and technical similarity (not supplied in your prompt).

---

How should investors and R&D teams map freedom-to-operate?

FTO checklist tied to the claims

For a freedom-to-operate screen around US 8,178,554, the operational questions are:

• Does your candidate active ingredient match trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide?
• Is the active used as a sodium salt?
• Does the product contain the claimed compound as an ingredient (composition claims 3-4)?
• Is it marketed or used for a bacterial infection indication (method claims 5-6)?
• Are you developing a combination regimen? The claims do not forbid combinations, so combination labeling can still support infringement if the claimed active is administered for bacterial infection.

Claim sensitivity to product design choices

Product decision	Effect vs US 8,178,554
Switching dosage form (tablet vs solution)	Usually does not avoid claim 3/4 if active matches
Switching salt form (sodium to another acceptable salt)	Often still stays within claim 1 if “pharmaceutically acceptable salt” applies
Changing indication (e.g., not bacterial infection)	Does not avoid claim 3/4 if composition contains active; reduces risk for method claims 5/6 depending on labeling and actual use
Changing stereochemistry/trans configuration	High risk for escape, because claim 1 is explicitly trans by structure
Changing sulphooxy group identity/position	High risk for escape, because claim 1 depends on exact substitution pattern

---

Competitive landscape view: where overlapping claims are likely to occur

Common sibling-patent pattern in US filings

For a molecule-level patent, the most common overlapping prior/follow-on layers are:

1. Continuation/divisional filings on the same family (same core, broader or narrower claim sets)
2. Salt-specific continuation (claiming sodium vs other counterions)
3. Formulation-specific claims (even though your provided claims are broad, other family members may narrow to specific dosage forms)
4. Use-expansion claims (different bacterial categories, prophylaxis vs treatment, or adjunct uses)

Given the tightness of your claim set (only 6 claims), the broader landscape may be carried by other family members rather than by this single patent.

Patentability and validity pressure points (claim-set-based)

With this compact claim scope, typical challenges that can appear in litigation or post-grant review include:

• Novelty/obviousness of the specific compound structure if similar scaffolds were previously disclosed
• Anticipation if the exact trans compound or sodium salt was already disclosed in prior art
• Written description and enablement for broad “pharmaceutically acceptable salt” language, if the application did not support a broad salt genus
• Indefiniteness risk is low for a structurally defined small molecule, but depends on specification detail not in your prompt

The claims as written are clear and structurally anchored, which usually lowers ambiguity-based attack angles compared to functional or broad class claims.

---

What do these claims mean for generics and follow-on developers?

Straight-line infringement theory

• If a follow-on company makes the molecule and sells a product containing it, they test against claim 3 and/or claim 4.
• If they also claim or practice the antibacterial use, they test against claim 5 and/or claim 6.
• If the active is the same molecule but not sodium salt, they still test against claim 1, and compositions can still fall under claim 3.

Supply-chain risk

• Even if a company sells active pharmaceutical ingredient (API) and another entity formulates it, composition and method claims can still become relevant depending on how the API is supplied, marketed, and used. The claim text itself is not process-limited.

---

Key takeaways for decision-makers

• US 8,178,554 is a molecule-centric patent with ingredient claims that are broad at the formulation level (claims 3-4) and broad on therapeutic category (claims 5-6).
• Claim 1 is the central risk driver because it covers the exact trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide in free base and any pharmaceutically acceptable salt.
• Claim 2 is a targeted escalation for sodium-salt products and can provide a second infringement path even where products are deliberately limited to a specific salt form.
• A competitor’s easiest escape lever is structural change, especially stereochemistry and substituent identity/position; dosage form changes do not provide meaningful protection under these claims.
• The therapeutic method is broadly framed (“bacterial infection”), so label and clinical use framing should be treated as part of infringement risk management.

---

FAQs

1. Is the patent limited to a specific dosing route or dosage form?
   No. Claims 3 and 4 require only that a pharmaceutical composition comprises the claimed compound (claim 1 or claim 2). The provided claim text does not specify dosage form or route.

2. Can another salt form avoid infringement?
   Switching away from sodium can reduce risk to claim 2, but claim 1 still covers the same trans compound as “a pharmaceutically acceptable salt,” which can include other counterions.

3. Does the patent cover only specific bacteria or infection sites?
   No. Claims 5 and 6 cover treating a “bacterial infection” without specifying organism type or infection site.

4. Is stereochemistry a key limitation?
   Yes. Claim 1 is expressly “trans,” and the compound identity is structurally defined. Changing stereochemistry can be a key differentiator.

5. What is the main infringement pathway for a marketed product?
   Ingredient-based infringement via claims 3-4 if the product contains the claimed compound (or sodium salt), and potential additional exposure via claims 5-6 if the product is used or promoted to treat bacterial infections.

---

References

[1] United States Patent 8,178,554, claims 1-6 (as provided in the prompt).

Drugs Protected by US Patent 8,178,554

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 8,178,554

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	00 10121	Aug 1, 2000

International Family Members for US Patent 8,178,554

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1307457		C 2016 055	Romania
African Regional IP Organization (ARIPO)	1614
Argentina	031716